Depletion of Cellular Cholesterol and Lipid Rafts Increases Shedding of CD30

Journal of Immunology

Volumn 172, Issue 7, 2004, Pages 4324-4331

  Von Tresckow, Bastian ^a   Kallen, Karl Josef ^b   Von Strandmann, Elke Pogge ^a   Borchmann, Peter ^a   Lange, Hans ^b   Engert, Andreas ^a   Hansen, Hinrich P ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b UNIVERSITY OF KIEL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD30 ANTIGEN; CHOLESTEROL; CHOLESTEROL OXIDASE; FILIPIN; HYPOCHOLESTEROLEMIC AGENT; METALLOPROTEINASE; METHYL BETA CYCLODEXTRIN; MEVINOLIN; TRITON X 100; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME;

ARTICLE; AUTOIMMUNE DISEASE; BLOOD LEVEL; CONTROLLED STUDY; DOWN REGULATION; ENZYME LOCALIZATION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; LIPID MEMBRANE; MOLECULAR INTERACTION; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DOMAIN; TH1 CELL;

EID: 1642357584     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.172.7.4324     Document Type: Article

References (46)

1. + T cells producing Th2-type cytokines. FASEB J. 9:81.
2. Durkop, H., U. Latza, M. Hummel, F. Eitelbach, B. Seed, and H. Stein. 1992. Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease. Cell 68:421.
3. Baker, S. J., and E. P. Reddy. 1998. Modulation of life and death by the TNF receptor superfamily, Oncogene 17:3261.
4. Schnell, R., P. Borchmann, H. Schulz, and A. Engert. 2002. Current strategies of antibody-based treatment in Hodgkin's disease. Ann. Oncol. 13:57.
5. Josimovic-Alasevic, O., H. Durkop, R. Schwarting, E. Backe, H. Stein, and T. Diamantstein. 1989. Ki-1 (CD30) antigen is released by Ki-1-positive tumor cells in vitro and in vivo. I. Partial characterization of soluble Ki-1 antigen and detection of the antigen in cell culture supernatants and in serum by an enzyme-linked immunosorbent assay. Eur. J. Immunol. 19:157.
6. Zinzani, P. L., S. Pileri, M. Bendandi, M. Buzzi, E. Sabattini, S. Ascani, F. Gherlinzoni, M. Magagnoli, P. Albertini, and S. Tura. 1998. Clinical implications of serum levels of soluble CD30 in 70 adult anaplastic large-cell lymphoma patients. J. Clin. Oncol. 16:1532.
7. Horie, R., and T. Watanabe. 1998. CD30: expression and function in health and disease. Semin. Immunol. 10:457.
8. Folster-Holst, R., T. Henseler, J. Wehde, H. Lemke, M. Weichenthal, E. Christophers, and H. P. Hansen. 2002. Soluble CD30 plasma concentrations correlate with disease activity in patients with atopic dermatitis. Acta Derm. Venereol. 82:245.
9. Caligaris Cappio, F., M. T. Bertero, M. Converso, A. Stacchini, F. Vinante, S. Romagnani, and G. Pizzolo. 1995. Circulating levels of soluble CD30, a marker of cells producing Th2-type cytokines, are increased in patients with systemic lupus erythematosus and correlate with disease activity. Clin. Exp. Rheumatol. 13:339.
10. Wang, G., H. Hansen, E. Tatsis, E. Csernok, H. Lemke, and W. L. Gross. 1997. High plasma levels of the soluble form of CD30 activation molecule reflect disease activity in patients with Wegener's granulomatosis. Am. J. Med. 102:517.
11. + T cells in rheumatoid arthritis: a counter-regulatory paradigm for Th1-driven diseases. Trends Immunol. 22:72.
12. Saraiva, M., P. Smith, P. G. Fallon, and A. Alcami. 2002. Inhibition of type 1 cytokine-mediated inflammation by a soluble CD30 homologue encoded by ectromelia (mousepox) virus. J. Exp. Med. 196:829.
13. McMillan, S. A., G. V. McDonnell, J. P. Douglas, A. G. Droogan, and S. A. Hawkins. 1998. Elevated serum and CSF levels of soluble CD30 during clinical remission in multiple sclerosis. Neurology 51:1156.
14. Gerli, R., C. Lunardi, and C. Pitzalis. 2002. Unmasking the anti-inflammatory cytokine response in rheumatoid synovitis. Rheumatology (Oxford) 41:1341.
15. Giovannoni, G., and D. H. Miller. 1999. Multiple sclerosis and its treatment. J. R. Coll. Physicians Lond. 33:315.
16. van Roon, J. A., J. W. Bijlsma, and F. P. Lafeber. 2002. Suppression of inflammation and joint destruction in rheumatoid arthritis may require a concerted action of Th2 cytokines. Curr. Opin. Investig. Drugs 3:1011.
17. Hansen, H. P., S. Dietrich, T. Kisseleva, T. Mokros, R. Mentlein, H. H. Lange, G. Murphy, and H. Lemke. 2000. CD30 shedding from Karpas 299 lymphoma cells is mediated by TNF-α-converting enzyme. J. Immunol. 165:6703.
18. Kojro, E., G. Gimpl, S. Lammich, W. Marz, and F. Fahrenholz. 2001. Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the α-secretase ADAM 10. Proc. Natl. Acad. Sci. USA 98:5815.
19. Ehehalt, R., P. Keller, C. Haass, C. Thiele, and K. Simons. 2003. Amyloidogenic processing of the Alzheimer β-amyloid precursor protein depends on lipid rafts. J. Cell Biol. 160:113.
20. Matthews, V., B. Schuster, S. Schutze, I. Bussmeyer, A. Ludwig, C. Hundhausen, T. Sadowski, P. Saftig, D. Hartmann, K. J. Kallen, and S. Rose-John. 2003. Cellular cholesterol depletion triggers shedding of the human interleukin-6 receptor by ADAM10 and ADAM17 (TACE). J. Biol. Chem. 278:38829.
21. Simons, K., and D. Toomre. 2000. Lipid rafts and signal transduction. Nat. Rev. Mol. Cell Biol. 1:31.
22. Kabouridis, P. S., J. Janzen, A. L. Magee, and S. C. Ley. 2000. Cholesterol depletion disrupts lipid rafts and modulates the activity of multiple signaling pathways in T lymphocytes. Eur. J. Immunol. 30:954.
23. Phong, M. C., P. Gutwein, S. Kadel, K. Hexel, P. Altevogt, O. Linderkamp, and B. Brenner. 2003. Molecular mechanisms of L-selectin-induced co-localization in rafts and shedding. Biochem. Biophys. Res. Commun. 300:563.
24. Gutwein, P. S. Mechtersheimer, S. Riedle, A. Stoeck, D. Gast, S. Joumaa, H. Zentgraf, M. Fogel, and D. P. Altevogt. 2003. ADAM10-mediated cleavage of L1 adhesion molecule at the cell surface and in released membrane vesicles. FASEB J. 17:292.
25. Horn-Lohrens, O., M. Tiemann, H. Lange, J. Kobarg, M. Hafner, H. Hansen, W. Sterry, R. M. Parwaresch, and H. Lemke. 1995. Shedding of the soluble form of CD30 from the Hodgkin-analogous cell line L540 is strongly inhibited by a new CD30-specific antibody (Ki-4). Int. J. Cancer 60:539.
26. Kallen, K. J., P. Quinn, and D. Allan. 1993. Effects of brefeldin A on sphingomyelin transport and lipid synthesis in BHK21 cells. Biochem. J. 289:307.
27. Blank, N., C. Gabler, M. Schiller, M. Kriegel, J. R. Kalden, and H. M. Lorenz. 2002. A fast, simple and sensitive method for the detection and quantification of detergent-resistant membranes. J. Immunol. Methods 271:25.
28. Amour, A., P. M. Slocombe, A. Webster, M. Butler, C. G. Knight, B. J. Smith, P. E. Stephens, C. Shelley, M. Hutton, V. Knauper, et al. 1998. TNF-α converting enzyme (TACE) is inhibited by TIMP-3. FEBS Lett. 435:39.
29. Samsonov, A. V., I. Mihalyov, and F. S. Cohen. 2001. Characterization of cholesterol-sphingomyelin domains and their dynamics in bilayer membranes. Biophys. J. 81:1486.
30. Froese, P., H. Lemke, J. Gerdes, B. Havsteen, R. Schwarting, H. Hansen, and H. Stein. 1987. Biochemical characterization and biosynthesis of the Ki-1 antigen in Hodgkin-derived and virus-transformed human B and T lymphoid cell lines. J. Immunol. 139:2081.
31. Slack, B. E., L. K. Ma, and C. C. Seah. 2001. Constitutive shedding of the amyloid precursor protein ectodomain is up-regulated by tumour necrosis factor-α converting enzyme. Biochem. J. 357:787.
32. Simons, K., and R. Ehehalt. 2002. Cholesterol, lipid rafts, and disease. J. Clin. Invest. 110:597.
33. Beck, G., G. Bottomley, D. Bradshaw, M. Brewster, M. Broadhurst, R. Devos, C. Hill, W. Johnson, H. J. Kim, S. Kirtland, et al. 2002. (E)-2(R)-[1(S)-(Hydroxycarbamoyl)-4-phenyl-3-butenyl]-2′-isobutyl-2′ -(methanesulfonyl)-4-methylvalerohydrazide (Ro 32-7315), a selective and orally active inhibitor of tumor necrosis factor-α convertase. J. Pharmacol. Exp. Ther. 302:390.
34. Amour, A., C. G. Knight, A. Webster, P. M. Slocombe, P. E. Stephens, V. Knauper, A. J. Docherty, and G. Murphy. 2000. The in vitro activity of ADAM-10 is inhibited by TIMP-1 and TIMP-3. FEBS Lett. 473:275.
35. Janes, P. W., S. C. Ley, A. I. Magee, and P. S. Kabouridis. 2000. The role of lipid rafts in T cell antigen receptor (TCR) signalling. Semin. Immunol. 12:23.
36. Horie, R., T. Watanabe, Y. Morishita, K. Ito, T. Ishida, Y. Kanegae, I. Saito, M. Higashihara, S. Mori, and M. E. Kadin. 2002. Ligand-independent signaling by overexpressed CD30 drives NF-κB activation in Hodgkin-Reed-Sternberg cells. Oncogene 21:2493.
37. Hao, M., S. Mukherjee, and F. R. Maxfield. 2001. Cholesterol depletion induces large scale domain segregation in living cell membranes. Proc. Natl. Acad. Sci. USA 98:13072.
38. Burger, K., G. Gimpl, and F. Fahrenholz. 2000. Regulation of receptor function by cholesterol. Cell. Mol. Life Sci. 57:1577.
39. Stuve, O., S. Youssef, L. Steinman, and S. S. Zamvil. 2003. Statins as potential therapeutic agents in neuroinflammatory disorders. Curr. Opin. Neurol. 16:393.
40. Youssef, S., O. Stuve, J. C. Patarroyo, P. J. Ruiz, J. L. Radosevich, E. M. Hur, M. Bravo, D. J. Mitchell, R. A. Sobel, L. Steinman, and S. S. Zamvil. 2002. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 420:78.
41. Aktas, O., S. Waiczies, A. Smorodchenko, J. Dorr, B. Seeger, T. Prozorovski, S. Sallach, M. Endres, S. Brocke, R. Nitsch, and F. Zipp. 2003. Treatment of relapsing paralysis in experimental encephalomyelitis by targeting Th1 cells through atorvastatin. J. Exp. Med. 197:725.
42. Leung, B. P., N. Sattar, A. Crilly, M. Prach, D. W. McCarey, H. Payne, R. Madhok, C. Campbell, J. A. Gracie, F. Y. Liew, and I. B. McInnes. 2003. A novel anti-inflammatory role for simvastatin in inflammatory arthritis. J. Immunol. 170:1524.
43. Frostegard, J., A. K. Ulfgren, P. Nyberg, U. Hedin, J. Swedenborg, U. Andersson, and G. K. Hansson. 1999. Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines. Atherosclerosis 145:33.
44. Benagiano, M., A. Azzurri, A. Ciervo, A. Amedei, C. Tamburini, M. Ferrari, J. L. Telford, C. T. Baldari, S. Romagnani, A. Cassone, et al. 2003. T helper type 1 lymphocytes drive inflammation in human atherosclerotic lesions. Proc. Natl. Acad. Sci. USA 100:6658.
45. Hargreaves, P. G., and A. Al-Shamkhani. 2002. Soluble CD30 binds to CD153 with high affinity and blocks transmembrane signaling by CD30. Eur. J. Immunol. 32:163.
46. Neuhaus, O., S. Strasser-Fuchs, F. Fazekas, B. C. Kieseier, G. Niederwieser, H. P. Hartung, and J. J. Archelos. 2002. Statins as immunomodulators: comparison with interferon-β 1b in MS. Neurology 59:990.